新的扫描精确地检测了产生激素的肾上腺瘤,为目前的方法提供了一种更安全、非侵入性的替代方法。 A new scan accurately detects hormone-producing adrenal tumors, offering a safer, non-invasive alternative to current methods.

在《核医学杂志》上公布的经过同行审查的新的第二阶段试验表明,[68Ga]Ga-Pentixafor PET/CT是一种安全、非侵入性成像方法,在发现主要的高血压荷尔蒙原因 -- -- 原aldosteronism -- -- 中产生肾上腺肾上腺瘤的单体 aldosterone-肾上腺瘤方面具有很高的特异性。 A new peer-reviewed Phase 2 trial published in the Journal of Nuclear Medicine shows that [68Ga]Ga-Pentixafor PET/CT is a safe, non-invasive imaging method with high specificity for detecting unilateral aldosterone-producing adrenal adenomas in primary aldosteronism, the leading hormonal cause of hypertension. 澳大利亚的研究由CASS基金会和医学研究未来基金资助,发现PET/CT结果与目前的黄金标准、肾上血管抽样以及外科结果之间有强烈一致。 The Australian study, funded by the CASS Foundation and Medical Research Future Fund, found strong agreement between PET/CT results and the current gold standard, adrenal vein sampling, as well as surgical outcomes. 大多数病人倾向于非侵入性扫描,结果支持推进第三阶段试验。 Most patients preferred the non-invasive scan, and the findings support advancing to Phase 3 trials. 这种技术可以改善获得准确诊断的机会并指导治疗外科手术,特别是随着新的高血压治疗的出现。 The technology could improve access to accurate diagnosis and guide curative surgery, especially as new hypertension treatments emerge.